Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Paul B. Chapman, Salvador Martín‐Algarra et al.|The Lancet|2012Cited by 3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated MelanomaJames Larkin, Antoni Ribas, Paolo A. Ascierto et al.|New England Journal of Medicine|2014Cited by 2k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialPaolo A. Ascierto, James Larkin, Grant A. McArthur et al.|The Lancet Oncology|2016Cited by 1k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Sophie Piperno‐Neumann, Jessica C. Hassel et al.|New England Journal of Medicine|2021Cited by 869
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Keith T. Flaherty, Dirk Schadendorf et al.|The Lancet Oncology|2017Cited by 491